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RESEARCH ARTICLE
miRNA- and cytokine-associated extracellular vesicles mediate squamous cell 
carcinomas
Joseph P. Flemminga*, Brianna L. Hilla*, Mohammed W. Haquea*, Jessica Raada, Claudine S. Bonderb, 
Larry A. Harshynec, Ulrich Rodecka, Adam Luginbuhld, James K. Wahl IIIe, Kenneth Y. Tsaif, Peter J. Wermutha, 
Andrew M. Overmillera† and Mỹ G. Mahoneya
aDepartment of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA, USA; bCentre for Cancer Biology, 
University of South Australia and SA Pathology, Adelaide, SA, Australia; cDepartment of Medical Oncology, Thomas Jefferson University, 
Philadelphia, PA, USA; dDepartment of Otolaryngology–Head and Neck Surgery, Thomas Jefferson University, Philadelphia, PA, USA; 
eDepartment of Oral Biology, University of Nebraska Medical Center, Lincoln, NE, USA; fDepartment of Tumor Biology, Moffitt Cancer Center, 
Tampa, FL, USA
ABSTRACT
Exosomes, or small extracellular vesicles (sEVs), serve as intercellular messengers with key roles in 
normal and pathological processes. Our previous work had demonstrated that Dsg2 expression in 
squamous cell carcinoma (SCC) cells enhanced both sEV secretion and loading of pro-mitogenic 
cargo. In this study, using wild-type Dsg2 and a mutant form that is unable to be palmitoylated 
(Dsg2cacs), we investigated the mechanism by which Dsg2 modulates SCC tumour development 
and progression through sEVs. We demonstrate that palmitoylation was required for Dsg2 to 
regulate sub-cellular localisation of lipid raft and endosomal proteins necessary for sEV biogen-
esis. Pharmacological inhibition of the endosomal pathway abrogated Dsg2-mediated sEV 
release. In murine xenograft models, Dsg2-expressing cells generated larger xenograft tumours 
as compared to cells expressing GFP or Dsg2cacs. Co-treatment with sEVs derived from Dsg2- 
over-expressing cells increased xenograft size. Cytokine profiling revealed, Dsg2 enhanced both 
soluble and sEV-associated IL-8 and miRNA profiling revealed, Dsg2 down-regulated both cellular 
and sEV-loaded miR-146a. miR-146a targets IRAK1, a serine-threonine kinase involved in IL-8 
signalling. Treatment with a miR-146a inhibitor up-regulated both IRAK1 and IL-8 expression. 
RNAseq analysis of HNSCC tumours revealed a correlation between Dsg2 and IL-8. Finally, 
elevated IL-8 plasma levels were detected in a subset of HNSCC patients who did not respond 
to immune checkpoint therapy, suggesting that these patients may benefit from prior anti-IL-8 
treatment. In summary, these results suggest that intercellular communication through cell-cell 
adhesion, cytokine release and secretion of EVs are coordinated, and critical for tumour growth 
and development, and may serve as potential prognostic markers to inform treatment options.
Abbreviations: Basal cell carcinomas, BCC; Betacellulin, BTC; 2-bromopalmitate, 2-Bromo; Cluster 
of differentiation, CD; Cytochrome c oxidase IV, COX IV; Desmoglein 2, Dsg2; Early endosome 
antigen 1, EEA1; Epidermal growth factor receptor substrate 15, EPS15; Extracellular vesicle, EV; 
Flotillin 1, Flot1; Glyceraldehyde-3-phosphate dehydrogenase, GAPH; Green fluorescent protein, 
GFP; Head and neck squamous cell carcinoma, HNSCC; Interleukin-1 receptor-associated kinase 1, 
IRAK1; Interleukin 8, IL-8; Large EV, lEV; MicroRNA, miR; Palmitoylacyltransferase, PAT; Ras-related 
protein 7 Rab7; Small EV, sEV; Squamous cell carcinoma, SCC; Tissue inhibitor of metalloprotei-
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Introduction
The coordinated response of cell-to-cell and cell-to- 
microenvironment communication plays a critical 
role in biological processes including embryogenesis, 
maintenance of homoeostasis and pathological condi-
tions [1]. During tumorigenesis, autocrine as well as 
paracrine signals from cancer cells enable growth, 
angiogenesis and metastasis. The three major forms 
of intercellular communication include direct cell-cell 
contacts, secretion of soluble regulatory factors such as 
cytokines, and the recently discovered release of spe-
cialised membranous extracellular vesicles (EVs) [2]. 
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However, whether these modes of communication are 
interconnected is far more complex than previously 
understood. It is well established that cytokines, EVs 
and cell surface presentation of adhesion proteins play 
a role in tumorigenesis but how they modulate, in 
context of each other, is not known.
Desmoglein 2 (Dsg2) is a transmembrane compo-
nent of desmosomal cell-cell adhesion structures, 
which provides tensile strength by linking the trans-
membrane adhesive components to the intermediate 
cytoskeletal keratin filaments [3]. Mutations in the 
human Dsg2 gene underlie some arrhythmogenic 
right ventricular cardiomyopathies [4]. Interestingly, 
in human pluripotent stem cells, Dsg2 is critical for 
self-renewal, embryonic body and teratoma formation, 
and mediates the epithelial-to-mesenchymal transition 
through a β-catenin/Slug pathway [5]. In mice, ablation 
of the Dsg2 gene results in loss of the trophectoderm 
layer in blastocysts and triggers embryonic lethality 
without affecting cell-cell adhesion [6]. Dsg2 is highly 
expressed in malignant epithelial cell lines and in the 
two most common skin cancers, basal cell carcinomas 
(BCCs) and SCCs [7,8]. Furthermore, Dsg2 promotes 
vasculogenic mimicry to increase tumour blood supply 
and is associated with poor prognosis in malignant 
melanoma [9,10]. Over-expression of Dsg2 also occurs 
in prostate and colon cancers, suggesting a role for 
Dsg2 in oncogenesis in a variety of epithelial-derived 
tumours [11]. In vitro, Dsg2 can activate multiple 
growth and survival signalling pathways, and enhances 
epithelial cell proliferation and migration [12,13]. 
Knockdown of Dsg2 in colonic epithelial carcinoma 
cells decreases proliferation and suppresses xenograft 
tumour growth in mice [14]. We have demonstrated 
that forced expression of Dsg2 in the epidermis of 
transgenic mice promotes epidermal hyperplasia and 
increases susceptibility to tumour development [12]. 
Furthermore, these transgenic mice provide several 
lines of evidence supporting a paracrine signalling 
role of Dsg2 including enhanced proliferation in a 
different cell compartment and activation of hedgehog 
signalling in the dermis [8,12]. Through Stat3, Dsg2 
up-regulates Gli1 and Ptch1, target genes of the Hh 
signalling pathway and compound Dsg2/Ptc1+/lacZ 
mice have accelerated development of BCCs and 
SCCs and tumorigenesis in response to chemical carci-
nogens [8,15].
We recently demonstrated that Dsg2 regulates sEV 
biogenesis, increases their mitogenic content including 
EGFR and c-Src, and enhances their pro-proliferative 
effects on dermal fibroblasts [13]. EVs are secreted by 
virtually every cell type and are stratified by their size 
or their mechanism of biogenesis [16]. They are a 
diverse population, including sEVs such as exosomes 
(30–150 nm), and large EVs (lEVs) such as microvesi-
cles (0.1–1 µm), apoptotic bodies (1–5 µm) and onco-
somes (1–10 µm). These vesicles may contain various 
RNA species, DNA, proteins and lipid cargo that can 
be taken up by distant cell types and alter the pheno-
type of these recipients [17]. sEVs are becoming 
increasingly associated as impactful contributors to 
intercellular signalling systems that likely play a crucial 
role in tumorigenesis and metastasis via alteration of 
the tumour microenvironment (TME) [18]. One of the 
critical factors transported via sEVs that modulate 
these processes are microRNA (miRNAs). miRNAs 
are post-transcriptional regulators of protein transla-
tion that alter both pro- and anti-oncogenic pathways 
[19]. Understanding the complement of miRNA pre-
sent in tumour-derived EVs, and their downstream 
targets, is crucial for the progression of our under-
standing of the TME and the development of novel 
therapeutic options.
In this study, we show that Dsg2 modulates sEV 
biogenesis in a palmitoylation-dependent manner by 
altering the sub-cellular localisation of proteins asso-
ciated with membrane rafts and the endosomal proces-
sing pathway. The pro-oncogenic effect and 
tumorigenicity of Dsg2 correlate with sEV levels. 
Furthermore, we show that sEVs released in response 
to Dsg2 are enriched in cytokines, most notably the 
pro-chemotactic and -angiogenic factors, IL-8. 
Interestingly, in both cells and sEVs, RNAseq detected 
down-regulation of miR-146a in response to Dsg2, 
which has been shown to target IRAK1, possibly 




Antibodies used for Western blotting: 6D8 Dsg2 (1:100); 
10D2 Dsg2 (1:100); from Invitrogen (Carlsbad, CA), 
cluster of differentiation 63 (CD63; 1:1000), interleukin 
8 (IL-8; 1:500); from Cell Signalling Technology 
(Danvers, MA), early endosome antigen 1 (EEA1; 
1:1000), epidermal growth factor receptor substrate 15 
(EPS15; 1:1000), flotillin 1 (Flot1; 1:1000), green fluores-
cent protein (GFP; 1:1000), cytochrome c oxidase IV 
(COX IV; 1:1000), glyceraldehyde-3-phosphate dehydro-
genase, (GAPDH; 1:3000); from Santa Cruz 
Biotechnology (Santa Cruz, CA), CD9 (1:500); from LI- 
COR Biosciences (Lincoln, NE), goat anti-rabbit or 
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-mouse Odyssey 800 (1:15,000) and 680 (1:20,000). 
Antibodies used for immunofluorescence: 10D2 Dsg2 
(1:2); Flot1 (1:100); EEA1 (1:200); EPS15 (1:200); Rab7 
(1:250, Cell Signalling Technology); from Molecular 
Probes (Eugene, OR), goat anti-rabbit and -mouse 
Alexa Fluor 488 and 594 (1:400).
Generation of Dsg2 mutant cell lines
The stop codon of the human Dsg2 cDNA was 
removed and sub-cloned into vector pEGFP-N1 
(Clontech, Mountain View, CA) upstream of the GFP 
as previously described in detail [13,20,21]. For 
Dsg2cacs cDNA, two cysteine point mutations were 
generated using the QuikChange site directed muta-
genesis kit (Stratagene, San Diego, CA) [20]. The 
mutated cDNAs were then sub-cloned into the retro-
viral expression vector LZRS-ms-neo and transfected 
into Phoenix cells to package retroviral particles. 
Human A431 (epidermoid skin carcinoma) or UM- 
SCC1 (oral SCC) cells were selected in medium con-
taining G418 (500 µg/mL) after retroviral transduction. 
While these SCC cell lines express some endogenous 
levels of Dsg2, forced expression of higher levels of 
wild-type or mutant Dsg2 was possible using transfec-
tion of retrovirus expression constructs.
Cell culture
Cell lines were plated at 3 × 106 cells per 100 mm dish 
in complete DMEM containing 10% FBS (Peak Serum, 
Fort Collins, CO) and P/S (Thermo Fisher, Waltham, 
MA) as previously described [13]. At 80% confluency, 
cells were cultivated in serum free media for 48 h. The 
conditioned media was then collected for EV purifica-
tion. Cells were trypsinised and counted 
(Haemocytometer, Thermo Fisher). For drug treat-
ment, cells were treated with 2-Bromopalmitate (50 
µM, Sigma, St. Louis, MO), GW4869 (10 µM, 
Cayman Chemical, Ann Arbour) or Bafilomycin A1 
(0.02 µM, Cayman Chemical) for 48 h in serum free 
medium and conditioned medium was collected for EV 
isolation and analysis.
Immunofluorescence
Cells grown on glass slides were washed in cold PBS, 
fixed in 4% PFA (Electron Microscopy Sciences, 
Hatfield, PA) for 15 min at room temperature (RT) 
and then permeabilised with 1% TX-100 in PBS for 5 
min at RT. Cells were blocked in 5% normal goat 
serum (NGS), 0.1 M glycine, 0.02% TX-100 in PBS 
for 1 h at RT and incubated in 1° Ab in blocking buffer 
at 4°C overnight. Cells were washed in PBS and incu-
bated in 2° Ab in blocking buffer for 1 h at RT. 
Following secondary incubation, cells were washed 
again in PBS and then incubated with DAPI (1:1000, 
Sigma) in PBS for 5 min. Cells were washed in PBS and 
mounted in Fluoromount-G (Southern Biotech, 
Birmingham, AL), and images were captured by A1R 
+ Nikon confocal microscopy (Melville, NY).
Western blotting analysis
For Western blotting, cells were washed in ice-cold PBS 
and lysed with lysis buffer (10 mM Tris pH 7.5, 150 mM 
NaCl, 0.5 mM EDTA, 0.1% SDS, 1% deoxycholate, 1% 
TX-100) supplemented with PMSF (1 µM), protease 
inhibitor cocktail (Thermo Fisher) and phosphatase inhi-
bitor cocktail (Thermo Fisher) and heated to 95°C for 10 
min in Laemmli buffer. Proteins were resolved over SDS- 
PAGE (Bio-Rad Labs, Hercules, CA) and transferred to 
nitrocellulose membrane. Non-specific sites were 
blocked with blocking buffer (5% BSA in TBS) and 
incubated in primary antibodies in blocking buffer (5% 
BSA in TBST (TBS + 1% TX-100)) overnight at 4°C. 
Membranes were washed in TBST and incubated with 
secondary antibody in blocking buffer for 1 h. Infrared 
bands were visualised by LI-COR Odyssey imaging sys-
tem (LI-COR Biosciences, Lincoln, NE).
Extracellular vesicle purification
EV purification was performed using sequential ultra-
centrifugation protocol [22]. Conditioned medium was 
collected and subjected to serial centrifugation at 300 × 
g (10 min), 16,000 × g (30 min), and then 120,000 × g 
(70 min; Ti45 rotor). The supernatant was aspirated 
and the sEV pellet washed 1× with ice-cold PBS, re- 
suspended in PBS and stored in −20°C. For iodixanol 
purification, the 120,000 × g pellet containing sEVs and 
co-contaminates was added to a 40% iodixanol solu-
tion, which was used as the bottom fraction of a 40%/ 
30%/5% density gradient. Samples were centrifuged at 
120,000 × g (Sorvall TH 641) O/N and 1 mL fractions 
were collected from the top for analysis.
Trypsin digestion
sEVs were incubated at 37°C for 20 min with 0.04% trypsin 
(Corning, Corning, NY) in a final volume of 12 µL. The 
reaction was stopped by heat inactivation in Laemmli 
buffer and samples were prepared for Western blotting.
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Nanoparticle tracking analysis
EVs were analysed using the NanoSight NS300 (Malvern 
Instrument, Westborough, MA) for size, shape and con-
centration. NanoSight employs laser illumination to pro-
voke light scattering and video capture of Brownian 
motion to determine the size distribution and concentra-
tion of particles in solution. EVs (diluted 1:250; ~107–109 
particles/mL) were injected with a syringe pump (infuse 
= 20, Malvern Instrument) and recorded (3 × 30-second 
captures) to determine the mean size and concentration 
of nanoparticles in each sample.
Transfection with miR-146a mimic and inhibitor
SCC A431 cells were seeded into six well plates at 2 × 
105 cells per well in DMEM containing 10% FBS and 
cultured until 80% confluent. Cells were then cultivated 
in serum free media for 12 h. MISSION negative con-
trol miRNA (#HMC0002; Sigma-Aldrich), miR-146a- 
5p mimic (#HMI0228; Sigma-Aldrich) or miR-146a-5p 
inhibitor (#HSTUD0228; Sigma-Aldrich) were trans-
fected into six wells for each cell line using 
Lipofectamine 2000 (Thermo Fisher) according to the 
manufacturer protocol. After 24 h, media was removed 
from cultures and cells were washed with ice-cold PBS. 
Triplicate wells of each treatment condition were lysed 
in either Trizol for total RNA isolation or RIPA buffer 
for cellular protein isolation and stored at −80°C for 
further analysis.
Tumour xenograft
A431 or UM-SCC1 cells over-expressing GFP, Dsg2/ 
GFP or Dsg2cacs/GFP were established as described 
previously [20]. Cells were trypsinised and re-sus-
pended in DMEM (1 × 107 cells/mL) and injected 
(100 µL) subcutaneously into the flanks of Balb/c 
SCID mice (8–9 weeks of age). For sEV treatments, 
20 µg of sEVs were injected at the time of tumour 
implantation. Tumour length and width were mea-
sured by caliper on a twice-weekly schedule beginning 
7 days post-injection. Mice were also weighed to moni-
tor general health. Experiments were to be terminated 
at 28 days post-injection, except where excessive 
tumour burden and decline in animal health necessi-
tated termination at earlier time points. Animals were 
sacrificed, and the tumour tissue was collected and 
fixed in OCT or formalin for histology or immunohis-
tochemistry. Note: all experiments conformed to the 
Thomas Jefferson University IACUC protocols and 
approval.
Murine blood plasma EV
Mice were sacrificed and blood collected by cardiac punc-
ture with a 1 mL syringe coated with 0.5 M EDTA. Blood 
was then centrifuged at 2000 RPM for 20 min and plasma 
was further centrifuged at maximum speed for 10 min. 
EVs were purified using IZON Science LTD’s (Medford, 
MA) size exclusion chromatography columns according 
to the manufacturer’s protocol. The purified samples 
were collected in five 200 µL fractions and analysed 
using nanoparticle tracking analysis.
RNAseq
For miRNAseq, total RNA was harvested from A431 
and A431-Dsg2/GFP cells and sEVs using the 
miRNeasy Kit according to manufacturer’s instruction 
(Qiagen, Germantown, MD). RNA quality (RIN) deter-
mination and sequencing was performed by Avera 
Health (Sioux Falls, SD). Reads were aligned to the 
Genome Reference Consortium Human Build 37 
(GRCh37), and the expression values were calculated 
and analysed by Partek Genomics Suite (http://www. 
partek.com). miRNAs with expression of RPKM ≥ 1 
were considered for further analysis. Analysis of var-
iance (ANOVA) was performed between all cell lines. 
Heatmaps were created using Morpheus, https://soft 
ware.broadinstitute.org/morpheus.
For gene expression in HNSCC tumour tissues, total 
RNA was isolated from HNSCC tumour tissues using 
RNeasy kits (Qiagen) and libraries were prepared using 
TruSeq Stranded Total RNA kit (Illumina, San Diego, 
CA) following manufacturer’s instructions. The final 
libraries were sequenced on NextSeq 500 using 75bp 
paired-end chemistry. Sequencing reads were aligned 
with the reference genome of Homo sapiens Ensembl 
Version GRCh38 and using information from the gene 
transfer format (.gtf) annotation from GENCODE ver-
sion GRCh38.p12 using RSEM [23]. Using RSEM’s cal-
culate-expression function, total read counts and 
normalised transcripts per million (TPM) were obtained. 
Batch effects or sample heterogeneity was tested before 
differential expression, using iSeqQC [24]. The DESeq2 
package [25] in R/Bioconductor was used to analyse 
differential gene expression. Scatter plot analysis was 
used to assess the correlation of IL-8 and Dsg2 expres-
sion, and R2 value provided to measure goodness-of-fit.
Real-time PCR
For qPCR, total RNA was collected from cells and sEVs 
with the miRNeasy RNA Isolation Kit-Cell & Plant 
(Exiqon, VedBaek, Denmark) according to 
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manufacturer’s protocol. cDNA construction of total 
RNA, including mature miRNAs, was performed with 
the Universal cDNA Synthesis Kit II (Exiqon) accord-
ing to manufacturer’s suggestion employing 10 ng of 
cellular or EV RNA. qPCR was performed with 
ExiLENT SYBR Green Master Mix (Exiqon) on the 
ABI Prism 7900HT Sequence Detection System 
(Applied Biosystems, Foster City, CA). For mRNAs: 
IL-8 forward (5ʹ-GTG CAG TTT TGC CAA GGA 
GT-3ʹ); IL-8 reverse (5ʹ-TTA TGA ATT CTC AGC 
CCT CTT CAA AAA CTT CTC-3ʹ); IRAK1 forward 
(5ʹ-TCA-GCT-TTG-GGG-TGG-TAG-TG-3ʹ); IRAK1 
reverse (5ʹ-TAG-ATC-TGC-ATG-GCG-ATG-GG-3ʹ); 
GAPDH forward (5ʹ-GGT GTG AAC CAT GAG 
AAG TAT G-3ʹ); GAPDH reverse (5ʹ-GAG TCC TTC 
CAC GAT ACC AAA G-3ʹ).
Cytokine antibody array
A431-GFP and -Dsg2/GFP cells were grown to con-
fluency in 10 cm2 tissue culture dishes and then incubated 
in serum-free medium for 48 h. Large and sEVs were 
isolated from conditioned medium by sequential ultra-
centrifugation and used to analyse a panel of 120 cyto-
kines and chemokines (C-series Human Cytokine 
Antibody Array C1000, AAH-CYT-1000-2; Raybiotech, 
Norcross, GA) according to manufacturer’s protocol. The 
quantification of dot intensity was performed in ImageJ 
following background subtraction, and the raw data nor-
malised to the array-specific positive control dots.
HNSCC patients’ plasma IL-8
Blood samples were collected from patients with 
HNSCCs enrolled in a window of opportunity trial of 
Nivolumab and Tadalafil (NCT03238365) at Thomas 
Jefferson University Hospital approved by the Thomas 
Jefferson University Institutional Review Board. Blood 
was collected in EDTA collection tubes at baseline and 
surgery. Plasma was isolated following centrifugation at 
300 × g for 20 min and was stored at −80°C. MILLIPLEX 
MAP Human Cytokine/Chemokine Magnetic Bead 
Panels (Millipore) were used to identify cytokines pre-
sent in plasma collected from HNSCC patients. Samples 
were analysed in triplicate by a FlexMAP 3D (Luminex) 
and standard curves were generated for each cytokine 
and median fluorescent intensities were transformed 
into concentrations by five-point, non-linear regression. 
Treatment effects were assessed by a pathologist. 
Patients whose tumours exhibited > 20% pathologic 
treatment effect at the primary site were deemed respon-
ders (N = 10) and those with 20% > were labelled non- 
responders (N = 18).
Statistics
Results are mean ± SEM of at least three independent 
experiments performed in triplicates. Two-tailed 
Student’s t test was performed where needed. A 
mixed model analysis was carried out using Prism 
and either Tukey’s post hoc or Dunnett’s post hoc 
tests where appropriate for repeated measures 
ANOVA. P ≤ 0.05*; P ≤ 0.01**; P ≤ 0.001***.
Results
Characterisation of EVs
To study EVs, we adopted the standard isolation pro-
tocol using sequential ultracentrifugation to remove 
live cells and apoptotic bodies and to purify lEVs and 
sEVs from A431 SCC cells (Figure 1(a)). EVs were 
characterised by nanoparticle tracking analysis (NTA) 
showing significantly overlapping sized particles in 
both lEV and sEV preparations (Figure 1(b)). 
Focusing on sEVs, electron micrographs revealed intact 
vesicles from approximately 30 nm (left panel) to 100 
nm (right panel) in diameter (Figure 1(c)). Western 
blotting analysis confirmed the enrichment of the tet-
raspanins CD63 and CD9 and the lipid raft protein 
Flot1 in sEVs as compared to total cell lysates (Figure 
1(d)) [21]. The mitochondrial protein COX IV was 
completely absent from sEVs indicating an absence of 
cellular contaminants. These results confirmed pre-
vious findings that sequential ultracentrifugation is a 
viable method to isolate sEVs from SCC cells [21,26]
Palmitoylation of Dsg2 modulates sEV release in 
SCC cells
Palmitoylation is a covalent attachment of the 16C- 
fatty acid, palmitate, to cysteine residues through thioe-
ster linkage, important for proper protein localisation, 
association with cellular membranes and lipid rafts, 
protein trafficking and desmosome assembly [20,27– 
30]. Disruption of palmitoylation has been implicated 
in several disease states including cancer and treat-
ments that target palmitoylated proteins or palmitoyla-
cyltransferases (PATs) have the potential therapeutic 
benefits [31]. We previously demonstrated that Dsg2 
modulates EV release [21] and that palmitoylation of 
Dsg2 is critical for desmosome assembly, protein turn-
over and cell-cell adhesion [20]. However, whether 
palmitoylation of Dsg2 is necessary for EV release is 
unknown. Here we generated the cell lines stably 
expressing GFP and Dsg2/GFP by retroviral infection 
as previously described in detail [20] and confirmed 
that up-regulation of Dsg2 in SCC cells enhanced sEV 
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release (Figure 2(e)). The effect of Dsg2 was abrogated 
when cells were treated with 50 µM 2-bromopalmitate, 
an irreversible inhibitor of PATs, which works through 
covalent attachment to the catalytic cysteine residue 
within the active site, thereby blocking the function of 
all cellular PATs (Figure 2(a)). These results suggest 
that protein palmitoylation plays a role in regulating 
sEV release. However, we could not rule out off-target 
effects on the other proteins critical for sEV biogenesis.
We recently identified the two cysteine residues 
(C635 and C637) in the juxtamembrane (intracellular 
anchor) domain of Dsg2 that, when mutated to alanine 
and serine (C635A/C637S; cacs), respectively, abrogates 
palmitoylation of Dsg2 [20]. Stable A431 SCC cell lines 
Figure 1. Characterisation of EVs by sequential ultracentrifugation. (A) Schematic diagram of the serial centrifugation steps used to 
isolate large and sEVs. (B) Dynamic light scattering measurement by nanoparticle tracking analysis (NTA) of EVs isolated from A431 
SCC cells illustrating the concentration and size of particles present. (C) SEVs were loaded on a formvar carbon-coated EM mesh grid 
and imaged on a transmission electron microscope showing vesicles ranging in size from approximately 30 nm (left) to 100 nm 
(right). Scale bar, 100 µm. (D) Proteins from sEVs and total cell lysates (TLC) of A431 cells were resolved over SDS-PAGE and 
immunoblotted for the tetraspanin markers (CD63 and CD9), lipid raft-associated protein (Flot1), mitochondrial protein (COXIV) and 
GAPDH for equal loading.
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were generated over-expressing constructs of Dsg2 
fused to monomeric enhanced GFP, Dsg2/GFP or 
Dsg2cacs/GFP (Figure 2(b)). Western blotting of total 
cell lysates showed the 160 kD endogenous Dsg2 pro-
tein in A431 cells expressing GFP (Figure 2(c)). An 
additional 190 kD band representing the Dsg2/GFP 
or Dsg2cacs/GFP fusion proteins was observed in 
those respective cells. Immunostaining for GFP con-
firmed cytoplasmic staining for GFP and cell-cell bor-
der staining for Dsg2/GFP and, to a lesser extent, 
Figure 2. Loss of Dsg2 palmitoylation reduces EV release. (A) A431 SCC cells stably expressing GFP or Dsg2/GFP were treated with 
the vehicle control (DMSO) or 2-bromopalmitate (2-Bromo) (50 uM). After 18 h, conditioned medium was collected and sEVs 
isolated and counted by NTA. Values presented as percent control. GFP, 100 ± 7.9; GFP + 2-Bromo, 96.6 ± 8.6; Dsg2/GFP, 338.1 ± 
123.7; Dsg2/GFP + 2-Bromo, 152.1 ± 10.7. N = 3. *P ≤ 0.05. (B) Schematic diagram showing the GFP, Dsg2/GFP and Dsg2cacs/GFP 
fusion constructs. Dsg2cacs/GFP contains the mutations C635A and C637S and was previously described to eliminate Dsg2’s 
palmitoylation [20]. (C) A431 SCC cells stably expressing GFP, Dsg2/GFP or Dsg2cacs/GFP as a palmitoylation deficient control. Cells 
were lysed and proteins resolved by SDS-PAGE and immunoblotted with antibodies against Dsg2 or GFP (endogenous Dsg2: lower 
160 kD band; exogenous Dsg2/GFP or Dsg2cacs/GFP upper band: 190 kD). GAPDH for equal loading. (D) Immunofluorescence of 
A431-GFP, -Dsg2/GFP or -Dsg2cacs/GFP using antibodies against Dsg2 and GFP and imaged by confocal microscopy. Scale bar, 50 
µm. (E) sEV production from A431 cells stably expressing GFP, Dsg2/GFP or Dsg2cacs/GFP. Values presented as percent control. GFP, 
100 ± 14.7; Dsg2/GFP, 190.5 ± 16.0; Dsg2cacs/GFP, 94.9 ± 29.7. N = 17. *P ≤ 0.05; **P ≤ 0.01. (F) EVs isolated by ultracentrifugation 
were separated over iodixanol gradient and fractions collected and processed for Western blotting.
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Dsg2cacs/GFP (upper panels; Figure 2(d)). Anti-Dsg2 
antibodies detected the endogenous Dsg2 in the GFP 
cells which was dramatically enhanced in Dsg2/GFP 
and Dsg2cacs/GFP cells (lower panels; Figure 2(d)). 
As anticipated, the Dsg2cacs/GFP cells displayed less 
distinct cell-cell border signals. The cytoplasmic GFP 
signal observed in the Dsg2/GFP or Dsg2cacs/GFP cells 
may result from cleavage of the GFP from Dsg2 or 
Dsg2cacs as the lower panels clearly show more Dsg2 
and Dsg2cacs protein.
sEVs were collected from conditioned media of cells 
expressing GFP, Dsg2/GFP and Dsg2cacs/GFP and ana-
lysed by NTA showing the effect of Dsg2 on EV biogen-
esis was dramatically abrogated in cells expressing 
palmitoylation-deficient Dsg2cacs (Figure 2(e)). Willms 
et al. reported two different sub-populations of small EVs, 
low- and high-density, with distinct molecular composi-
tion and biological properties [32]. Here, by bottom- 
loading, density gradient separation we observed CD63 
(sEV marker) predominantly in the low-density, 5% 
iodixanol fractions 3 and 4 (top and middle panels; 
Figure 2(f)). Loss of Dsg2 palmitoylation dramatically 
shifted CD63 into the high-density 30–40% iodixanol 
fractions 7–9 (lower panel; Figure 2(f)). These results 
suggest that palmitoylation of Dsg2 is essential for proper 
cargo loading into low-density sEVs and disturbing pal-
mitoylation induces more high-density sEVs, while still 
reducing sEV biogenesis as a whole.
Dsg2 modulates sEV biogenesis through the 
endocytic pathway
To further elucidate the mechanism by which Dsg2 
promotes sEV release, we examined the effect of Dsg2 
on the endocytic pathway. We first examined the 
effects of Dsg2 on Flot1, EPS15, EEA1 or Rab7. Flot1 
is an integral membrane protein that forms discrete 
planar micro-domains in lipid rafts and is involved in 
endocytosis, signal transduction and the regulation of 
cytoskeletal elements [33]. Importantly, Flot1 localises 
to the plasma membrane and has been detected in early 
endosomes and EVs. Here, shown by immunofluores-
cence (Figure 3(a)) and immunoblotting (Figure 3(b)), 
Dsg2 increased not only the expression of Flot1 as 
shown in the graphs depicting quantitation of immu-
noblot band intensity, but also promoted membrane 
association. As previously mentioned, palmitoylation is 
important for proper protein localisation and associa-
tion with cellular membranes and lipid rafts. As such, 
the loss of Dsg2 palmitoylation reduced the effect on 
Flot1 in Dsg2cacs/GFP expressing cells (Figure 3(a,b)) 
Similar results were observed with EPS15, a scaffolding 
adaptor protein associated with clathrin-coated pits, 
responsible for endocytosis of cargo from outside of 
the cell (Figure 3(a,b)). The effect of Dsg2 on EEA1, an 
early endosomal protein acting as a ligand for Rab5 
binding to endocytic vesicles or Rab7, a late endosomal 
protein, was less pronounced (Figure 3(a,b)). It is 
important to appreciate the difference in Western blot-
ting and immunofluorescence when interpreting this 
data. Immunofluorescence may have certain biases 
towards cell compartments such as the plasma mem-
brane, while quantitation of Western blotting bands 
shows the total cellular levels. For this reason, the 
differential production of the endocytic markers is 
less apparent in the Western blot images in comparison 
to the immunofluorescence..
To confirm that the endosomal pathway is involved 
in Dsg2-mediated sEV release, A431-GFP and A431- 
Dsg2/GFP cells were treated with the drug inhibitors 
GW4869 and Bafilomycin A1 (BafA1). sEVs were iso-
lated and counted by NTA. GW4869 is a neutral sphin-
gomyelinase inhibitor that blocks ceramide-mediated 
inward budding of multi-vesicular bodies (MVBs) and 
the fusion of MVBs to the plasma membrane to release 
sEVs. Here, GW4869 reduced sEV release (Figure 3 
(c)). BafA1, on the other hand, inhibits vacuolar-type 
proton ATPase (V-ATPase) preventing the acidifica-
tion and fusion of the MVBs to the lysosomes and 
drives sEV release [34]. Treatment with BafA1 
increased sEV release (Figure 3(c)). The effect was 
more dramatic with A431-Dsg2/GFP, as compared to 
A431-GFP cells. The results thus far suggest that Dsg2 
modulates sEV release through membrane invagination 
and the endocytic pathway.
sEVs enhance SCC tumour development
To assess the effect of sEVs in xenograft tumour devel-
opment, immunocompromised mice were injected sub-
cutaneously with A431 cells over-expressing GFP, 
Dsg2/GFP or Dsg2cacs/GFP (Figure 4(a)). Over the 
course of 3–4 weeks, the Dsg2/GFP expressing cells 
developed significantly larger tumours than their GFP 
or Dsg2cacs/GFP expressing counterparts. Similar 
results were obtained using the head and neck SCC 
UM-SCC1 cells (Figure 4(b)). These findings suggest 
that Dsg2 enhanced tumour development in both cuta-
neous and head and neck SCCs. To rule out loss of 
Dsg2 expression in the non-palmitoylated Dsg2cacs/ 
GFP cells, xenograft tissues were immunostained for 
GFP. We observed strong GFP signals in all xenografts 
demonstrating that the cells could maintain expression 
of the recombinant GFP or Dsg2 constructs through-
out the duration of the experiment. Cytoplasmic stain-
ing was observed with A431-GFP xenografts while the 
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Figure 3. Dsg2 alters early endocytic pathways and endosomal trafficking. (A) A431 cells expressing GFP, Dsg2/GFP and Dsg2cacs/ 
GFP were seeded, immunostained for Dsg2, Flot1, EPS15, EEA1 and Rab7 and then imaged by confocal microscopy. Note the sub- 
cellular localisation of Flot1, EPS15 and to some less extent EEA1 in the A431-Dsg2/GFP cells, which are reduced with the abrogation 
of Dsg2 function by the cacs mutation (A431-Dsg2cacs/GFP). Scale bar, 20 µm. *P ≤ 0.05. (B) Lysates of A431 cells expressing GFP, 
Dsg2/GFP or Dsg2cacs/GFP were resolved over SDS-PAGE and immunoblotted for Dsg2, endocytic pathway proteins (Flot1, EPS15, 
EEA1) and GAPDH. Western blot was quantified using ImageStudio and signals were normalised to the GFP cell line. N = 3. Flot1 
(GFP, 100 ± 0.0; Dsg2/GFP, 148.9 ± 14.5; Dsg2cacs/GFP, 100.6 ± 11.0); EPS15 (GFP, 100 ± 0; Dsg2/GFP, 146.1 ± 12.5; Dsg2cacs/GFP, 
108.2 ± 5.2); EEA1 (GFP, 100 ± 0; Dsg2/GFP, 142.3 ± 11.1; Dsg2cacs/GFP, 89.2 ± 17.1). (C) A431-GFP and A431-Dsg2/GFP cells were 
treated with GW489 and bafilomycin A1 for 48 h. sEVs were isolated and quantitated. A431-GFP (control, 100 ± 5.3; GW4869, 86.6 ± 
10.8; BafA1, 247.1 ± 17.1); A431-Dsg2/GFP (control, 279.4 ± 65.5; GW4869, 99.9 ± 54.3; BafA1, 960.1 ± 153.0). N = 3. *P ≤ 0.05, **P ≤ 
0.01.
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A431-Dsg2/GFP xenografts showed distinct cell-cell 
border staining (Figure 4(c)). Similar to the in vitro 
results (Figure 2(c)), while the Dsg2cacs/GFP cells 
expressed high levels of the mutated Dsg2, the staining 
was less punctated at the cell border (Figure 4(c)). 
These results confirm that the cells retained their abil-
ity to express the transgene in vivo. Although we have 
observed increased proliferation in response to Dsg2 
over-expression in vitro, the exact parameters allowing 
us to resolve the difference in growth rates between the 
cell lines were experimentally determined at very low 
cell densities (~5 × 103 cells). Considering that our in 
vivo results are at densities ~3.5 orders of magnitude 
higher than these in vitro observations, we sought to 
explore other mechanisms to explain the difference in 
tumour growth.
Next, to assess whether the increased tumour 
volume correlates with sEV release, blood plasma was 
isolated from the xenografted mice upon the comple-
tion of experiments. sEVs were isolated by IZON qEV 
Figure 3. (continued)
10 J. P. FLEMMING ET AL.
Figure 4. The pro-tumorigenic effect of Dsg2 is abrogated with loss of palmitoylation and rescued with EV treatment. (A) 
Immunocompromised Balb/c SCID mice were subcutaneously injected with 1 × 106 of A431-GFP, -Dsg2/GFP or – Dsg2cacs/GFP 
cells. Tumour growth was measured, and average tumour volumes were calculated to determine the tumorigenicity for each cell 
line. N = 8, 13, 16, respectively. Tumour volume in mm3: Day 7 (GFP, 2.0 ± 1.4; Dsg2/GFP, 14.5 ± 4.8; Dsg2cacs/GFP, 2.2 ± 1.3); Day 9 
(GFP, 7.5 ± 3.7; Dsg2/GFP, 96.3 ± 31.3; Dsg2cacs/GFP, 29.1 ± 9.4); Day 14 (GFP, 57.9 ± 19.0; Dsg2/GFP, 323.3 ± 45.3; Dsg2cacs/GFP, 
104.4 ± 17.2); Day 17 (GFP, 81.3 ± 22.4; Dsg2/GFP, 596.2 ± 133.7; Dsg2cacs/GFP, 146.4 ± 25.8); Day 21 (GFP, 157.1 ± 39.8 Dsg2/GFP, 
768.0 ± 162.5; Dsg2cacs/GFP, 279.5 ± 42.9). *, A431-Dsg2/GFP vs A431-GFP; Δ, A431-Dsg2/GFP vs A431-Dsg2cacs/GFP. (B) UM-SCC1 
cells were used to establish lines over-expressing GFP, Dsg2/GFP or Dsg2cacs/GFP and injected subcutaneously in SCID mice to 
establish tumour xenografts in the flanks as described above. Tumour volume was measured weekly. Tumour volume in mm3: Day 7 
(GFP, 4.1 ± 2.6; Dsg2/GFP, 16.4 ± 5.6; Dsg2cacs/GFP, 21.1 ± 5.5); Day 10 (GFP, 17.0 ± 3.9; Dsg2/GFP, 70.8 ± 11.6; Dsg2cacs/GFP, 47.7 
± 8.8); Day 14 (GFP, 56.8 ± 4.7; Dsg2/GFP, 227.4 ± 56.0; Dsg2cacs/GFP, 143.8 ± 34.9); Day 17 (GFP, 124.2 ± 25.0; Dsg2/GFP, 351.1 ± 
53.6; Dsg2cacs/GFP, 224.1 ± 44.3); Day 19 (GFP, 147.1 ± 20.2; Dsg2/GFP, 429.1 ± 69.5; Dsg2cacs/GFP, 245.9 ± 43.9); Day 24 (GFP, 
292.1 ± 56.0; Dsg2/GFP, 486.6 ± 59.0; Dsg2cacs/GFP, 410.6 ± 60.7). *, UM-SCC1-Dsg2/GFP vs UM-SCC1-GFP; Δ, UM-SCC1-Dsg2/GFP 
vs UM-SCC1-Dsg2cacs/GFP. N = 9, 16, 15, respectively. (C) Immunofluorescence of tumour sections derived from A431-GFP, -Dsg2/ 
GFP and -Dsg2cacs/GFP xenografts in vivo showing sub-cellular localisation of Dsg2. Nuclei stained with DAPI (blue). Scale bar = 10 
µm. (D) EVs were isolated by IZON size exclusion chromatography from blood plasma of mice in (A) and counted by NTA. Values 
presented as percent control. GFP, 100 ± 24.5; Dsg2/GFP, 255.1 ± 47.3; Dsg2cacs/GFP, 144.8 ± 20.5. *P ≤ 0.05; **P ≤ 0.01. (E) 
Immunocompromised Balb/c SCID mice were subcutaneously injected with 1 × 106 of A431-GFP, A431-Dsg2/GFP or A431-GFP along 
with A431-Dsg2/GFP-derived sEVs. Tumour growth was measured, and average tumour volumes were calculated to determine the 
tumorigenicity of each cell line N = 5, 4, 7, respectively. Tumour volume in mm3: Day 7 (GFP, 2.4 ± 2.2; GFP + sEV, 11.4 ± 7.1; Dsg2/ 
GFP, 11.4 ± 7.1); Day 10 (GFP, 6.4 ± 3.8; GFP + sEV, 11.4 ± 20.8; Dsg2/GFP, 69.4 ± 13.4); Day 14 (GFP, 19.1 ± 8.2; GFP+sEV, 40.3 ± 
65.2; Dsg2/GFP, 303.8 ± 113.4); Day 17 (GFP, 96.2 ± 39.0; GFP+sEV, 181.7 ± 79.3; Dsg2/GFP, 558.0 ± 171.8); Day 21 (GFP, 109.9 ± 
46.9; GFP+sEV, 377.5 ± 190.6; Dsg2/GFP, 683.1 ± 133.1); Day 24 (GFP152.7 ± 61.7; GFP+sEV, 516.0 ± 253.1; Dsg2/GFP, 891.2 ± 
137.5); Day 26 (GFP, 165.0 ± 75.9; GFP + sEV, 608.2 ± 292.6; Dsg2/GFP, 1162.6 ± 201.5). *, A431-Dsg2/GFP vs A431-GFP; Δ, A431- 
Dsg2/GFP vs A431-Dsg2cacs/GFP; *P ≤ 0.05; **P ≤ 0.01.
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column chromatography according to the manufac-
turer’s instructions and sEVs counted by NTA. 
Similar to the in vitro findings in Figure 2(e), larger 
number of sEVs was detected in circulating plasma of 
mice carrying A431-Dsg2/GFP xenografts as compared 
to A431-GFP (Figure 4(d)). While the number of 
plasma sEVs in A431-Dsg2cacs/GFP mice was signifi-
cantly higher than those with A431-GFP, it was signif-
icantly reduced compared to the A431-Dsg2/GFP 
(Figure 4(d)). To further demonstrate that the increase 
in tumour development is mediated through vesicles, 
sEVs were isolated from A431-Dsg2/GFP cells and co- 
injected with the A431-GFP cells in xenografts. Despite 
having been exposed to just a single dose of 20 µg 
sEVs, we observed a marked and significant increase 
in tumour size compared to the A431-GFP cells co- 
injected with a PBS volume control (Figure 4(e)). Thus 
far, the results suggest that Dsg2 enhances SCC tumour 
development possibly through sEV release and that a 
single dose of sEVs enhances the tumorigenic potential 
of the SCC cells.
Dsg2 enhances EV-bound cytokine release
Cytokines are small molecular weight soluble factors 
with a wide range of biological functions and have been 
shown to play a critical role in tumour cell growth and 
progression, angiogenesis, and metastasis. To explore 
the alteration of cytokine release in response to Dsg2 
expression and to elucidate the mechanism by which 
sEVs promote tumour development, we employed a 
human secretome antibody array using conditioned 
medium (contains all EVs), lEVs and sEVs isolated by 
ultracentrifugation from A431-GFP and A431-Dsg2/ 
GFP cells (Figure 5(a)). Results were normalised to 
the array-specific negative (black boxes) and positive 
(blue boxes) control signal and plotted (Figure 5(b,c)). 
In response to Dsg2, the secretion of eight cytokines 
was up-regulated while two were down-regulated in the 
conditioned medium (Figure 5(b) and Table 1). No 
major changes in cytokines were observed in lEVs. 
However, in sEVs 11 cytokines were enhanced in 
response Dsg2 (Figure 5(c) and Table 2). EGFR as 
well as the ligand betacellulin (BTC) were markedly 
enriched in sEVs but not in the conditioned medium. 
On the other hand, the tissue inhibitor metalloprotei-
nases 1 and 2 (TIMP1 and 2), highly involved in most 
cancers, were found at high levels in the control cells 
and TIMP2 was slightly enriched in the conditioned 
medium in response to Dsg2 (Figure 5(b,c)). However, 
both TIMP1 and 2 were significantly reduced in the 
sEV samples as compared to the conditioned medium 
(Figure 5(b,c)). Interestingly IL-8, a potent angiogenic 
and chemotactic factor known to play a role in tumour 
development and immune recruitment [35], was 
enriched in sEVs. These results suggest a mechanism 
of active sorting into sEVs, which served as our reason-
ing to pursue this further as a possible mechanism.
To further confirm that IL-8 was present specifically 
in sEVs and not contaminant particles or protein 
aggregates, A431-Dsg2/GFP sEVs from ultracentrifuga-
tion were resolved over an iodixanol gradient to 
remove aggregate contaminants (Figure 6(a)). 
Proteins from the CD63 enriched fraction (*, Figure 6 
(a)) were harvested and incubated with the cytokine 
array to confirm the presence of IL-8. Recent evidence 
supports the presence of several cytokines including IL- 
8 on the surface of EVs, and therefore able to activate 
its receptors on recipient cells [36]. Here, to determine 
whether IL-8 was present on the surface of sEVs, iodix-
anol purified samples from fraction 4 (*, Figure 6(a)) 
were treated with trypsin, which degraded the surface 
IL-8 while maintaining EV integrity suggesting its loca-
tion to be on the outside of the vesicles (Figure 6(c)). 
This is as opposed to GAPDH level, which was largely 
unchanged due to its localisation to the inside of sEVs.
Dsg2 regulates IL-8 by down-regulating miR-146a
miRNAs are small non-coding RNA molecules that are 
emerging as important regulators of diverse biological 
processes and miRNA-dependent regulation of the IL-8 
gene has been reported in many pathological conditions 
including inflammation and cancer [37–41]. In addition, 
miR-146a modulates senescence and inflammation by 
targeting IL-8 [42,43]. To investigate the role of Dsg2 in 
the regulation of miRNAs, miRNA-sequencing (miRNA- 
Seq) on cellular and sEV-derived miRNAs from A431 
and A431-Dsg2/GFP cells was performed. The results of 
the RNA-Seq analysis showed that 93 total cellular 
miRNAs were altered (50 up-regulated and 43 down- 
regulated) in response to Dsg2 (Figure 7(a) and Table 
3). In sEVs, 19 miRNAs changed in response to Dsg2 
with 16 up-regulated and 3 down-regulated. Of those, 
only 8 of the 19 were similar between the cells and 
sEVs, suggesting that some miRNAs were selectively 
and actively packaged into sEVs. Interestingly, 
miR146a-5p (miR146a) was the most down-regulated 
miRNA in response to Dsg2 at both the cellular level as 
well as in sEVs (Figure 7(a)). The mechanism by which 
Dsg2 modulates miRNAs remains to be determined.
While miR-146a does not directly target IL-8, it does 
inhibit IRAK1 and its ability to activate transcription of 
NFkB target genes such as IL-8, thereby regulating IL-8 
expression [44,45]. To examine the direct effect of 
miR-146a on IL-8 and IRAK1, A431 cells were treated 
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with miR-146a mimic or inhibitor, with scrambled 
miRNA as control. IL-8 (Figure 7(b)) and IRAK1 
(Figure 7(c)) expression was analysed by qPCR. The 
miR-146a mimic decreased both IRAK1 and IL-8 
expression while the inhibitor increased their expres-
sion levels suggesting that Dsg2 may modulate IL-8 
expression through down-regulation of miR-146a.
Correlation between Dsg2 and IL-8 and 
responsiveness to immune checkpoint therapy
IL-8 and Dsg2 have been shown up-regulated in HNSCCs 
[21,46]. Here, we analysed the correlation between Dsg2 
and IL-8 levels in 14 HNSCC tumour tissues using 
RNAseq showing a moderate Pearson correlation coeffi-
cient (R2 = 0.52; P = 0.0035) between Dsg2 and IL-8 
expression (Figure 8(a)). To further establish the relevance 
of our current findings in an in vivo setting, we assessed the 
correlation of circulating blood levels of IL-8 and response 
to immune checkpoint therapy. Blood plasma was col-
lected from HNSCC patients (n = 28) prior to treatment 
with the PD-1 inhibitor, Nivolumab and IL-8 level was 
measured by ELISA. Subsequent to treatment, patients 
were stratified according to clinical response to 
Nivolumab (red = non-responder and blue = responder) 
showing those who responded to the drug treatment had 
significantly lower levels of IL-8 as compared to those that 
did not show a positive response (Figure 8(b)). These 
Figure 5. Dsg2 enhances the release of the pro-inflammatory cytokine IL-8 through EVs. (A) Human cytokine antibody array C6 and 
C7 were assayed with conditioned medium, large or sEVs harvested from A431-GFP and A431-Dsg2/GFP cells and processed 
according to the manufacturer’s protocol. Blue boxes, positive controls; black boxes, negative controls; red boxes, IL-8 signals. [(B) 
and (C)] Densitometry was performed on each cytokine by ImageJ software. Histogram bars represent the relative intensity value of 
each cytokine altered in response to Dsg2 (blue: A431-GFP; red: A431-Dsg2/GFP) from conditioned medium (B) or sEVs (C). Data 
were normalised to on-membrane positive control and depicted as relative abundance in samples ± SEM. N = 2.
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results suggest that those with lower levels of circulating 
IL-8 responded better to immune checkpoint therapy.
Discussion
Here we present evidence that the pro-oncogenic, stem 
cell marker Dsg2 promotes SCC development and 
progression through down-regulation of miR-146a, 
resulting in increased production of IL-8, packaged 
and released in sEVs (Figure 9). These findings are 
supported by clinical data showing that low plasma 
levels of IL-8 correlate with HNSCC patients’ respon-
siveness to immune checkpoint therapy.
Figure 5. (countiued)
Table 1. Changes in cytokines secreted by squamous carci-
noma cells in response to Dsg2.
Conditioned medium                               
Array protein Class Fold change P value
IL-6 Chemoattractant 2.22 4.2E-3
GM-CSF Growth factor 1.95 5.2E-3
ICAM-1 Adhesion molecule 1.74 3.6E-2
IGFBP-6 Growth factor 1.67 1.8E-2
IL-8 Chemoattractant 1.57 3.3E-2
PDGF-BB Growth factor 1.49 9.5E-3
TNFRI Cell surface receptor 1.30 1.5E-3
TIMP2 Metalloproteinase inhibitor 1.11 2.3E-2
GROa/b/g Chemoattractant 0.76 1.2E-2
CCL5 Chemoattractant 0.51 5.6E-3
Table 2. Changes in cytokines associated with small extracel-
lular vesicles secreted by squamous carcinoma cells in response 
to Dsg2.
Small extracellular vesicles                            
Array protein Class Fold change P value
I-TAC Chemoattractant 5.46 4.3E-4
IL-8 Chemoattractant 5.36 8.3E-3
MIP-1B Chemoattractant 3.56 9.6E-3
ANGPT2 Growth factor 2.80 1.4E-2
CCL28 Chemoattractant 2.52 1.1E-2
BTC Growth factor 2.31 2.4E-2
EGFR Growth factor receptor 2.22 2.2E-2
TRAIL (R4) TRAIL-binding protein 2.05 4.2E-2
IGFBP-3 Growth factor 1.73 1.3E-2
Dtk Receptor tyrosine kinase 1.49 3.8E-2
ICAM-1 Adhesion molecule 1.59 4.4E-2
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During sEV biogenesis, proteins are internalised 
through the plasma membrane into endocytic vesicles, 
which merge to form early endosomes and then are 
sorted for recycling, degradation or secretion [47]. The 
role of post-translational modifications of membrane 
proteins in this dynamic process is not fully under-
stood. Palmitoylation is a reversible lipid modification 
that influences protein conformation and stability, pro-
tein-protein interaction and membrane trafficking. 
Protein palmitoylation is regulated by palmitoyl acyl-
transferases. Strong evidence supports a link between 
protein palmitoylation and EV biogenesis and many of 
these palmitoylated proteins are enriched in sEVs 
including Dsg2 [48–50]. Here we demonstrate that 
the palmitoylation state of Dsg2 is critical for traffick-
ing of membrane raft proteins and early endosomal 
proteins (Figure 3(a)) and thereby modulates sEV 
release (Figure 2(d)). These results suggest that muta-
tion at these cysteines affects the function of Dsg2 or 
other proteins and pathways in modulating sEV 
release. This study does not eliminate the likelihood 
of other conserved cysteines across different effector 
proteins that may also play a role in sEV biogenesis, 
nor does it rule out the possibility for cysteines to be 
modified in other ways (i.e. nitrosylation). 
Interestingly, Flot1 showed a congruent relationship 
with the palmitoylation of Dsg2, in its localisation to 
the cell borders in SCC cells (Figure 3(a)). The role of 
palmitoylation of Dsg2 in influencing lipid raft 
dynamics and exosome release still remains unclear.
Altered protein palmitoylation has been implicated 
in several disease states including cancer and 
Figure 6. IL-8 is present on the surface of sEVs. (A) Conditioned medium derived from A431-Dsg2/GFP cells was used to isolate sEVs 
by sequential ultracentrifugation and iodixanol separation. Fractions were collected from the top and immunoblotted for CD63. (B) 
Fraction 4, enriched in CD63, was digested with trypsin (0.2%) and then subjected to Western blotting analysis for IL-8 and GAPDH.
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Table 3. Dsg2-dependent miRNA changes in cells and EVs. RNAseq data for miRNA expression in A431 SCC cells in response to 
Dsg2. Complete list of 93 cellular and 19 EV miRNAs modified in response to Dsg2.
Cells                                       Extracellular vesicles
miRNA P value Fold change miRNA P value Fold change
hsa-miR-4751 3.4E-02 3.494971 hsa-miR-148a-5p 2.6E-02 3.160165
hsa-miR-3614-3p 2.4E-02 3.457813 hsa-miR-1249-3p 8.0E-04 3.010493
hsa-miR-155-5p 1.6E-02 2.466088 hsa-miR-155-5p 5.5E-02 2.948538
hsa-miR-489-3p 4.7E-02 2.396844 hsa-miR-574-3p 2.6E-02 2.394957
hsa-miR-1343-3p 1.4E-02 2.178318 hsa-miR-1237-5p 7.7E-03 2.361985
hsa-miR-335-3p 2.2E-02 2.173783 hsa-miR-1296-5p 3.7E-02 2.329467
hsa-miR-1268b 1.7E-02 2.08478 hsa-miR-4746-5p 4.8E-02 2.265768
hsa-miR-941 3.7E-03 2.015638 hsa-miR-589-5p 5.1E-02 2.114036
hsa-miR-1303 4.3E-03 2.006902 hsa-miR-486-5p 4.1E-02 1.931873
hsa-miR-550a-3-5p 5.4E-02 1.988431 hsa-miR-210-3p 5.3E-02 1.905276
hsa-miR-339-5p 2.0E-02 1.978894 hsa-miR-769-5p 5.4E-02 1.547565
hsa-miR-125b-5p 3.7E-02 1.936007 hsa-miR-25-3p 1.4E-02 1.375542
hsa-miR-345-5p 1.5E-03 1.921073 hsa-miR-30d-5p 3.3E-02 1.301342
hsa-miR-378a-5p 5.2E-02 1.901527 hsa-let-7a-5p 0.0E + 00 1.265757
hsa-miR-222-3p 2.3E-02 1.859522 hsa-miR-328-3p 2.1E-02 1.172835
hsa-miR-455-3p 8.7E-03 1.854454 hsa-miR-95-3p 3.7E-02 1.132884
hsa-miR-3935 4.4E-02 1.842817 hsa-miR-103a-3p 5.3E-02 −1.10957
hsa-miR-1268a 3.3E-03 1.824421 hsa-miR-181a-2-3p 1.9E-03 −1.60214
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approaches that target palmitoylated proteins and pal-
mitoyl acyltransferases have the potential for therapeu-
tic intervention [51]. Given that Dsg2 can promote 
activation of mitogenic signalling cascades and enhance 
tumorigenesis, palmitoylation may play a role in the 
ability of Dsg2 to promote these properties [8,13]. 
Although the relationship between EV biogenesis and 
Dsg2 palmitoylation remains unclear, it is proposed to 
be dependent on the ability of Dsg2 to interact with 
lipid raft proteins that have both signalling and struc-
tural manifestations. In xenograft models, Dsg2 pro-
motes larger tumours (Figure 4(a,b)) and the effect was 
dramatically reduced with the cells over-expressing 
unpalmitoylated Dsg2 (i.e. Dsg2cacs). This was not 
due to the rate of cell growth as palmitoylation did 
not have an effect on cell proliferation. We previously 
showed that palmitoylation-deficient Dsg2 is unstable 
and is degraded by lysosomes more rapidly than WT 
Dsg2 [20]. However, some palmitoylation-deficient 
Dsg2, that is incorporated into desmosomes, remain 
relatively stable (Figure 4(c)). To our knowledge, this is 
the first demonstration of expression of an unpalmi-
toylated protein (Dsg2cacs) in the in vivo setting 
(Figure 4(c)).
In skin, sEVs are secreted by a variety of cell types 
including epithelial keratinocytes, stromal fibroblast and 
immune cells. While it is well known that sEVs contribute 
to tumour development and progression, it remains 
unclear the source of sEVs or its content that play a 
critical role during malignant transformation. While we 
cannot rule out the systemic effects on other cells, a single 
dose of sEVs derived from SCC cells over-expressing 
Dsg2 is capable of enhancing the tumorigenic potential 
of SCC cells in vivo (Figure 4(d)). As the number of 
clinical trials using sEVs are increasing each year, there 
is an urgent need to better understand their tissue-specific 
content to develop more targeted therapeutic treatments. 
Paracrine factors associated with sEVs become key 
players modulating the TME, including cytokines and 
miRNAs and their interplay is crucial for maintaining 
homoeostasis. Released during normal response to infec-
tion or wound repair, cytokines have the potential to 
inhibit cancer development. However, cancer cells have 
hijacked this system by expressing receptors that upon 
activation, can promote proliferation and survival.
The recent findings that cytokines are encapsulated 
or associated with sEVs allow the cell-cell communica-
tion systems to intertwine and facilitate cell stimula-
tion. The cytokine array analysis here showed only two 
proteins (IL-8 and ICAM-1) overlapped between the 
conditioned medium (Figure 5(b)) and the sEVs 
(Figure 5(c)). This raises the possibility that 8 of the 
10 cytokines altered by Dsg2 in the conditioned med-
ium are soluble and not associated with sEVs. 
Conversely, 10 of the 12 proteins detected in sEVs 
may be EV-encapsulated (Figure 5(c)) and thereby 
not detected in the conditioned medium (Figure 5 
(b)). We propose that in response to Dsg2, ICAM-1 
and IL-8 are up-regulated and bound to the surface of 
sEVs. ICAM-1 is up-regulated in many cancers includ-
ing breast cancer and oral SCCs [52,53]. Furthermore, 
a membrane-associated form of ICAM-1 associates 
Table 3. (Continued). 
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with exosomes and can inhibit leukocytes from binding 
to activated endothelial cells [54]. It is not clear from 
these results whether this is the full length ICAM-1 or 
soluble form of ICAM-1. Likewise, IL-8 is secreted by 
oral SCC cells and has been detected on the surface of 
exosomes [36,55]. These findings are in congruent with 
our results here that Dsg2-mediated up-regulation of 
IL-8 is associated with sEVs.
While IL-8 is found predominantly in the soluble 
form, we do not believe that this undermines the 
importance of our findings concerning IL-8 asso-
ciated with sEVs. Here, we have shown that sEVs, 
which are already known to be powerful mediators 
of cell signalling, can now act as conduits for cyto-
kine signalling. The active sorting of IL-8 onto the 
surface of vesicles ties IL-8 signalling to the plethora 
of potential targets and downstream functions of 
EVs. This effect was mediated by purified EV thus 
demonstrating that the effect can occur independent 
of the presence of soluble IL-8. Association with 
sEVs may increase the local concentration of IL-8 
as well as protect it from degradation by circulating 
proteases.
The mechanism by which Dsg2 activates malignant 
transformation and oncogenesis remains to be deter-
mined. Here, RNAseq shows dramatic down-regulation 
of miR-146a (Figure 7(a)) which targets the interleu-
kin-1 receptor-associated kinase 1 (IRAK1) (Figure 7 
(c)) [56]. IRAK1 belongs to the serine-threonine kinase 
family that is involved in Toll-like receptor and IL-1 
signalling activation which promotes gene expression 
of IL-6 and IL-8. Thus, down-regulation of miR-146a 
as observed here in response to Dsg2, would promote 
IL-8 expression and release (Figure 7(b)). IL-8 is a pro- 
inflammatory cytokine that plays a critical role in 
tumour progression and metastasis and is up-regulated 
in many cancers including oral SCCs [44,46]. A corre-
lation between expression of Dsg2 and IL-8 was 
Figure 7. Dsg2 alters IL-8 and IRAK1 through miR-146a. (A) The expression of 93 total cellular and 19 EV miRNAs altered in response 
to Dsg2 detected by RNASeq (signal > 500 and P = 0.05) as reflected by log-normalised intensities. [(B) and (C)] SCC A341 cells were 
treated with scrambled control, miR-146a mimic or miR-146a inhibitor for 24 h and total RNA was isolated. RT-qPCR performed for 
IL-8 (B) and IRAK1 (C) and expression levels were normalised to GAPDH (N = 9). For IL-8: Untreated, 1.0 ± 0.2; Scramble, 1.4 ± 0.2; 
Mimic 0.4 ± 0.3; Inhibitor, 1.7 ± 0.1. For IRAK1: Untreated, 1.0 ± 0.5; Scramble, 1.3 ± 0.9; Mimic 0.35 ± 0.1; Inhibitor 7.1 ± 04.1.
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observed in HNSCC tumours (Figure 8(a)), and in 
patients’ blood plasma, we detected varying levels of 
IL-8 (Figure 8(b)). Interestingly, patients with higher 
basal levels of IL-8 were less responsive to checkpoint 
inhibitor treatment (Nivolumab), suggesting that treat-
ment with IL-8 or Dsg2 inhibitor to down-regulate IL- 
8 levels may significantly improve the response of 
patients to anti-PD-1 inhibitors.
Our data support previously unexplored roles of 
Dsg2, establishing this protein as a modulator of 
pro-inflammatory cytokines and the early endosomal 
pathway, thus impacting sEV release. In summary, 
the results obtained from this study elucidate a novel 
function of Dsg2 and shed new light on Dsg2’s 
ability to influence the tumour microenvironment 
via paracrine mechanisms. Through linking cytokine 
signalling to EV biology, we hope that future studies 
will build on our work and lead to novel therapies 
for SCCs, HNSCC and any cancers linked to Dsg2 
dysregulation.
Figure 8. Relationship between tumoural Dsg2 and IL-8 and plasma IL-8 with responsiveness to check-point inhibitor treatment. (A) 
Gene expression in tumour tissues was determined by RNA seq (NextSeq 500 using 75bp paired-end chemistry at a depth of 50 
million reads). Scatter plot analysis is used to assess the association of IL-8 and Dsg2. R2 value is provided to measure goodness-of- 
fit. (B) HNSCC patients (N = 28) were stratified according to clinical response: non-responders (red; N = 18) and responders (blue; N 
= 10). Plot shows baseline plasma levels of IL-8 analysed by ELISA. Non-responders, 753 ± 223; responders, 151 ± 32. Statistical 
significance was assessed using ANOVA (* = P < 0.008).
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